Successful 3-day lung preservation using a cyclic normothermic ex vivo lung perfusion strategy
- PMID: 35952495
- PMCID: PMC9385559
- DOI: 10.1016/j.ebiom.2022.104210
Successful 3-day lung preservation using a cyclic normothermic ex vivo lung perfusion strategy
Abstract
Background: Cold static preservation (CSP) at higher temperatures (10°C) has been recently shown as an optimal strategy up to 24-36h of preservation. Here, we hypothesized that alternating 10°C static storage with cycles of normothermic ex vivo lung perfusion (EVLP) would provide conditions for cellular "recharge", allowing for multi-day lung preservation.
Methods: Donor lungs from male Yorkshire pigs were preserved using 10°C CSP with two cycles of 4h EVLP. After a total of 3 days of preservation, a left lung transplant was performed followed by 4h of graft evaluation. As controls, 2 lungs were preserved solely with continuous 10°C preservation for 3 days and transplanted.
Findings: For animals receiving lungs preserved using a cyclic EVLP protocol, lung function and histological structures were stable and the recipient systemic partial pressure of oxygen/fraction of inspired oxygen (P/F Ratio) after excluding the contralateral lung was 422 ± 61 mmHg. In contrast, lungs preserved solely in continuous cold static storage at 10°C for 72h developed massive lung failure, resulting in recipient death. Metabolomic analysis revealed that EVLP plays a critical role in the re-vitalization of key central carbon energy metabolites (Glucose, Succinate, N-Acetyl Aspartate) and reducing the expression of the inflammasome activation marker CASP1.
Interpretation: In conclusion, we demonstrate for the first time the feasibility of 3-day lung preservation leading to excellent early post-transplant outcomes. The thoughtful combination of cold storage (10°C) and intermittent EVLP can open new opportunities in organ transplantation.
Funding: This work was supported by the UHN Foundation (Grant#1013612).
Keywords: Ex vivo lung perfusion; Lung preservation; Lung transplant; Metabolomics.
Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of interests MC, TW and SK are shareholders of Traferox Technologies Inc and consultants for Lung Bioengineering. MC, AA, TW, SK have an international patent pending pertaining to donor organ preservation using both static cold storage and ex vivo organ perfusion has been filed (17/714,593).
Figures
References
-
- Chambers DC, Yusen RD, Cherikh WS, et al. The registry of the international society for heart and lung transplantation: thirty-fourth adult lung and heart-lung transplantation report—2017; focus theme: allograft ischemic time. J Hear Lung Transplant. 2017;36(10):1047–1059. - PubMed
-
- Ali A, Wang A, Ribeiro RVP, et al. Static lung storage at 10°C maintains mitochondrial health and preserves donor organ function. Sci Transl Med. 2021;13(611):1–14. - PubMed
-
- Cypel M, Rubacha M, Yeung J, et al. Normothermic Ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant. 2009;9(10):2262–2269. - PubMed
-
- Hsin MKY, Iskender I, Nakajima D, et al. Extension of donor lung preservation with hypothermic storage after normothermic ex vivo lung perfusion. J Hear Lung Transplant. 2016;35(1):130–136. - PubMed
-
- Yeung JC, Krueger T, Yasufuku K, et al. Outcomes after transplantation of lungs preserved for more than 12 h: a retrospective study. Lancet Respir Med. 2016;2600(16):1–6. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
